Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 11 CNS 10 Gastrointestinal 8 Breast 5 Head & Neck 4 Sarcoma 3 Genitourinary 3 Other solid neoplasm 2 Endocrine 2 Tumor-Agnostic 1 Other neoplasm 1 NET 1

Conditions

Pheochromocytoma 1 Paraganglioma 1 Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 32 Everolimus 19 Magnetic Resonance Spectroscopy 14 gallium Ga 68 dotatate 12 Temozolomide 12 Nivolumab 11 Capecitabine 10 pembrolizumab 9 lanreotide 9 cabozantinib 8 Positron Emission Tomography Computed Tomography 8 177Lu-octreotide, DOTA(0)-Tyr(3)- 8 Ga(III)-DOTATOC 7 3-Iodobenzylguanidine 7 Somatostatin 6 Octreotide 6 Lutetium-177 6 Carboplatin 6 90Y-octreotide, DOTA-Tyr(3)- 6 telotristat ethyl 5 surufatinib 5 lenvatinib 5 Ipilimumab 5 Fluorodeoxyglucose F18 5 pasireotide 4 copper dotatate CU-64 4 avelumab 4 Single Photon Emission Computed Tomography Computed Tomography 4 Positron-Emission Tomography 4 Bevacizumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × vandetanib × NET × Clear all

NCT01941849 2015-12-21

VIBRaNT

University College, London

Phase 1 Withdrawn

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡